Allogene Therapeutics (ALLO) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed Editas Medicine (EDIT) over the past year, gaining 5.9% versus a loss of 30.0%. Over five years, ALLO leads with a -91.3% price change compared with -92.8% for EDIT. Allogene Therapeutics is the larger company by market cap ($494.1 million vs $422.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | EDIT |
|---|---|---|
| Share price | $1.43 | $2.75 |
| Market cap | $494.05M | $422.35M |
| 1-day change | -2.05% | +0.73% |
| YTD return | +4.38% | +34.15% |
| 1-year return | +5.93% | -30.03% |
| 5-year return | -91.32% | -92.77% |
| EPS (TTM) | $-0.66 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $4.33 |
| 52-week low | $1.04 | $1.66 |
| Distance from 52-week high | -67.94% | -36.49% |
| Analyst consensus | none | buy |
| Avg. price target upside | +529.37% | +114.55% |
| Average volume | 5.78M | 2.48M |
| Shares outstanding | 345.49M | 153.58M |
| Employees | 150 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed EDIT by 36.0 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
ALLO vs EDIT FAQ
Which is bigger, Allogene Therapeutics or Editas Medicine?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $494.05M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, ALLO or EDIT?
ALLO returned +5.93% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Editas Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.